Exciting news for patients with #diabetes as Glooko and Better Therapeutics unveil agreement to integrate AspyreRx digital behavioral treatment into Glooko’s diabetes management platform. Canaan’s Wende Hutton sits on the Glooko board. #remotepatientmonitoring businesswire.com/news/home/2024…

Thrilled to share news of Nina Kjellson appointment to the board of Foundation for the National Institutes of Health. We’re excited to watch her contributions to the group’s ongoing efforts to foster #research, support #scientific pioneers, and accelerate #patient breakthroughs. businesswire.com/news/home/2024…

Promising clinical data from Transposon for TPN-101 in the treatment of #neurodegenerative diseases #PSP #ALS. Co is shining example of Canaan's belief in building companies with talented entrepreneurs. Check out the company’s data press release here: transposonrx.com/pdf/Transposon…

Nocion Therapeutics has raised a $62M Series B to support its efforts to develop a novel treatment for chronic #cough. We are pleased to have participated and have our Julie Papanek Grant on the board. Read more about the company and its Series B here: nociontx.com/nocion-therape…

Happy to share exciting news from @sardonatx on the appointment of Cristina Csimma to its board of directors as executive chair. She will join Canaan's Nina Kjellson on the board, and help support the company as it works to advance its innovative #precision #oncology approach.

Congrats to Qlaris Bio for initiating two P2 studies of QLS-111, a 1st-in-class #glaucoma treatment that targets a component of intraocular pressure that is not addressed by other therapies. Canaan’s Wende Hutton sits on its BOD. qlaris.bio/qlaris-bios-no…

Big additions to Hyalex team. Dr. Thomas Vail joins as chief medical officer with deep scientific and clinical expertise in the #orthopaedicsfield. Adam Gridley brings his impressive operational and transactional track record to the board. prnewswire.com/news-releases/…

Canaan making news with big additions. Proud to add Uwe Schoenbeck, Ph.D., to the #healthcare team. Also happy to bring $100M+ in new capital on board to be deployed by #biopharma team. Have now raised $1B+ since early 2023. canaan.com/latest/canaan-…

$24M Series B round raised by Qlaris Bio - funds will support continued clinical development of QLS-111, first-in-class #glaucoma drug candidate. Compound currently in two Phase 2 studies (Osprey and Apteryx). Canaan’s Wende Hutton sits on its board. qlaris.bio/qlaris-bio-com…

Fast Track designation from #FDA for Transposon's TPN-101 for Progressive Supranuclear Palsy. 1st treatment to reduce NfL and IL-6, key biomarkers of #neurodegeneration and #neuroinfllammation in #PSP transposonrx.com/pdf/Transposon…

Our portfolio company, Grey Wolf Therapeutics, has raised a $50M Series B+ round. Continues to make clinical progress with lead #immuno-oncology asset & will now expand R&D into #autoimmunedisease with its novel #antigen modulation technology. greywolftherapeutics.com/grey-wolf-ther…

Congrats to the Grey Wolf Therapeutics team for presenting the 1st clinical data on its lead #immunooncologycandidate at #ASCO 2024. Encouraging early results as the company now moves into the study's combo treatment cohorts. greywolftherapeutics.com/grey-wolf-ther…

Antiva Bio announces top-tier Scientific and Development Advisory Board. Thought leaders will provide great insight & guidance as company advances development of ABI-2280 for #HPVinfection and the pre-cancerous lesions that the infection causes. antivabio.com/news/2024/0613…

We're excited to announce our Series A investment in Aim Security and our partnership with Matan Getz + Adir Gruss to solve some of the biggest security challenges in the industry today. Read more from Joydeep Bhattacharyy here: linkedin.com/pulse/harnessi…

ThirtyFiveBio gets 2nd prestigious Biomedical Catalyst grant from Innovate UK in less than a year. Will support novel GPR35 inhibition approach to treating GI disease and cancers. Canaan’s Brent Ahrens sits on BOD. 30fivebio.com/643k-grant-awa…

Pathios Therapeutics appoints Paul G. Higham and his > 20 years of executive biotech experience as CEO. Founding CEO, Stuart Hughes, transitions to CSO to focus on 1st-of-its-kind GPR65 inhibition approach to #immuno-oncology. pathiostherapeutics.com/paul-higham-ce…

Big splash this morning from CatalYm as news of its oversubscribed $150M Series D financing is gaining broad attention throughout the biotech space. Canaan is proud to have co-led this round and congrats to our own Colleen Cuffaro who sits on the board. catalym.com/catalym-announ…

Proud to participate in Autobahn Therapeutics' $100M Series C round. As part of the fundraise, our own Uwe Schoenbeck has joined the Autobahn board. Excited to follow progress as company advances novel #neuropsychiatric and #neuroimmunologictherapies autobahntx.com/news/autobahn-…

Excited about today's financing news from Halda Therapeutics, a company trailblazing RIPTAC™ therapeutics, a new class of #precision medicines to defeat #cancer. Congrats to Canaan’s own Tim Shannon, who serves as the company’s executive chair. haldatx.com/halda-therapeu…

🚨 NuVentures brings a new series of webinars with TiE Bangalore ahead of TiE Global Summit. We begin with an important topic - TAKING INDIAN COMPANIES GLOBAL. With Shekhar Kirani , Joydeep Bhattacharyya, Krishna Depura, and Venk Krishnan. Register now : bit.ly/475Uram